Factors influencing plasma phenobarbitone levels in epileptic patients.

1 Various statistical techniques were used to study the effects of age, sex and concurrent therapy with other anticonvulsants on the relation between plasma phenobarbitone levels and doses of (i) phenobarbtione, (ii) methylphenobarbitone or (iii) primidone, in epileptic patients. 2 Methylphenobarbitone and primidone are converted to phenobarbitone in the body. The mean doses of phenobarbitone, methylphenobarbitone and primidone which produced the same plasma phenobarbitone level (15 microgram/ml) were, respectively, 1.75,2.75 and 7.75 mg kg-1 day-1. 3 For both phenobarbitone and methylphenobarbitone dose requirement to achieve a given plasma phenobarbitone level fell progressively with age. Sex influenced the relation between plasma phenobarbitone level and phenobarbitone or methylphenobarbitone dose. Interactions were detected between primidone and both phenytoin and carbamazepine. 4 In individual patients, within the limits of dosage studied, the relation between plasma phenobarbitone level and drug dose was not rectilinear if phenobarbitone itself was taken, but was rectilinear if methylphenobarbitone was taken.

[1]  E. Reynolds.  Drug treatment of epilepsy , 1994, Lancet.

[2]  M. Eadie,et al.  Simutaneous assay of methylphenobarbitone and phenobarbitone using gas—liquid chromatography with on-colum butylation , 1975 .

[3]  P. Fenwick,et al.  Interaction of phenytoin and primidone. , 1975, British medical journal.

[4]  M. Eadie,et al.  Simultaneous assay of methylphenobarbitone and phenobarbitone using gas-liquid chromatography with on-column butylation. , 1975, Journal of chromatography.

[5]  A. Richens.  Drug Estimation in the Treatment of Epilepsy , 1974, Proceedings of the Royal Society of Medicine.

[6]  M. Eadie,et al.  Preliminary observations on the clinical pharmacology of carbamazepine ('Tegretol'). , 1974, Proceedings of the Australian Association of Neurologists.

[7]  G. Wilkinson,et al.  Chronic and severe phenobarbital intoxication in a child treated with primidone and diphenylhydantoin. , 1973, The Journal of pediatrics.

[8]  M. Eadie,et al.  Diphenylhydantoin dosage. , 1973, Proceedings of the Australian Association of Neurologists.

[9]  G. Glaser,et al.  Variation in response to anticonvulsants in a group of epileptic patients. , 1972, Transactions of the American Neurological Association.

[10]  C. R. Craig,et al.  Metabolism and anticonvulsant properties of mephobarbital and phenobarbital in rats. , 1971, The Journal of pharmacology and experimental therapeutics.

[11]  C. Tassinari,et al.  A Clinical Study of Serum Primidone Levels , 1970, Epilepsia.

[12]  B. B. Gallagher,et al.  The Relationship of the Anticonvulsant Properties of Primidone to Phenobarbital , 1970, Epilepsia.

[13]  F. Mcdowell,et al.  The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes , 1969, Neurology.

[14]  J. Wallace.  Simultaneous spectrophotometric determination of diphenylhydantoin and phenobarbital in biologic specimens. , 1969, Clinical chemistry.

[15]  L. C. Mark.  Metabolism of barbiturates in man , 1963 .

[16]  T. Butler,et al.  N‐mythelated derivatives of barbituric acid, hydantoin and oxazolidinedione used in the treatment of epilepsy , 1958, Neurology.

[17]  A. Hauptmann.  Luminal bei Epilepsie , 1912 .